Teal Health, headquartered in San Francisco (USA), has achieved a significant milestone in its mission to improve cervical cancer screening options. The company has been granted Breakthrough Device designation by the US Food and Drug Administration (FDA) for its at-home self-collect cervical cancer screening device, the Teal Wand. This designation follows the successful completion of Teal Health’s clinical trial. The trial surpassed enrollment targets and generated robust clinical performance data, leading to the FDA’s recognition of the device’s potential to enhance diagnosis or treatment of life-threatening diseases. Femtech Insider